New Presentation

Investor Presentation

View our latest Investor Presentation

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Latest Annual Filing

Fiscal Year Ended Dec 31, 2017

View Filing

Sign me up for:


Stock Information

Company Overview

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of  activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Heat Biologics, Inc.
801 Capitola Drive
Suite 12
Durham, NC 27713
T: +1 919 240 7133
info@heatbio.com

Investor Relations

investorrelations@heatbio.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
T: +1 212 509 4000